- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- epoetin alfa, placebo
- Biological · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,023
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Male Subjects
- Interventions
- Savolitinib, Fluvoxamine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Prostatic Neoplasms
- Interventions
- MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Sleep Initiation and Maintenance Disorders, Insomnia
- Interventions
- GW679769
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 13
- States / cities
- Glendale, Arizona • Glendale, California • Hallandale, Florida + 10 more
- Conditions
- Mild to Heavy Alcohol Consumption
- Interventions
- Oxycodone
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lymphoma
- Interventions
- denileukin diftitox, dexamethasone
- Biological · Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 11
- States / cities
- Miami, Florida • Chicago, Illinois • New Orleans, Louisiana + 8 more
- Conditions
- Carcinoid Tumors
- Interventions
- Pasireotide (SOM230)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more
- Conditions
- Healthy
- Interventions
- Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Head and Neck Cancer Survivors, Cancer of the Head and Neck Surviors
- Interventions
- Ototoxicity Screening Protocol
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
- Interventions
- Palifermin
- Drug
- Lead sponsor
- Brett King
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Bridgeport, Connecticut • New Haven, Connecticut
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep, Eating Disorders, Physical Activity, Loneliness, Stress
- Interventions
- Not listed
- Lead sponsor
- Aura
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 912 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Galactose
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 2 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Drug Related Problems Post Hospital Discharge, Healthcare Utilization, Discharge Medication Counseling
- Interventions
- RPh Counseling + Outpatient Med Dispensing at Discharge, Discharge Med Dispensing Plus Counseling - Current Practice
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Adverse Drug Reaction (ADR), Polypharmacy Patients
- Interventions
- Not listed
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Bryan, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Concord, California • Covina, California + 106 more
- Conditions
- Bacterial Infections, Mycoses, HIV Infections
- Interventions
- Clarithromycin, Rifabutin, Sulfamethoxazole-Trimethoprim, Dapsone, Fluconazole
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 2
- States / cities
- San Francisco, California • Seattle, Washington
- Conditions
- Healthy
- Interventions
- ARV-471, Rosuvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Major Depressive Disorder
- Interventions
- LY03005, Pristiq
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Cancer
- Interventions
- Warfarin, Ketoconazole, Gemfibrozil, GSK2118436 150mg, GSK2118436 75mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Sarasota, Florida • Detroit, Michigan + 5 more
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 15
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- Healthy
- Interventions
- modafinil, methylphenidate, lorazepam, placebo
- Drug
- Lead sponsor
- Orasi Medical, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Elk Grove Village, Illinois
- Conditions
- Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
- Interventions
- Active inhaled cannabis, Placebo, Active Oral Ethanol
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Interventions
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Diagnostic Test · Device · Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Healthy
- Interventions
- Darifenacin, Tolterodine, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 18 more